Skip to main content
. Author manuscript; available in PMC: 2013 Oct 23.
Published in final edited form as: J Immunol. 2001 Sep 15;167(6):3478–3485. doi: 10.4049/jimmunol.167.6.3478

Table I.

Survival of DBA/2 islet allografts in B6AF1 recipients treated with CTLA4/Fc and IL-15 mutant/Fc

Donor Recipient Treatmenta Islet Graft Survival (days)
DBA/2 B6AF1 Untreated 11, 11, 11, 12, 13, 13, 15, 17, 17, 20
DBA/2 B6AF1 CTLA4/Fc 20, 31, 34, 51, >120, >120, >120, >120
DBA/2 B6AF1 IL-15m/Fc 15, 22, 29, 32, >120, >120, >120, >120
DBA/2 B6AF1 CTLA4/Fc + IL-15m/Fc >120, >120, >120, >120
a

Treatment: CTLA4/Fc, 0.1 mg/day, i.p. from days 0 to 11 posttransplantation; IL-15m/Fc, 1.5 µg/day, i.p. from days 0 to 21 posttransplantation.